Thomas H. McLean

Human HDAC7 Harbors a Class IIa Histone Deacetylase-specific Zinc Binding Motif and Cryptic Deacetylase Activity

A. Schuetz, Jinrong Min, Abdellah Allali‐Hassani et al. · Journal of Biological Chemistry · 2008 · 258 citations · Full text

Life Sciences, Molecular Biology, Oncology +10

1-Aminomethylbenzocycloalkanes:  Conformationally Restricted Hallucinogenic Phenethylamine Analogues as Functionally Selective 5-HT_2AReceptor Agonists

Thomas H. McLean, Jason C. Parrish, M. Braden et al. · Journal of Medicinal Chemistry · 2006 · 115 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Sulfur-Substituted α-Alkyl Phenethylamines as Selective and Reversible MAO-A Inhibitors:  Biological Activities, CoMFA Analysis, and Active Site Modeling

Alejandra Gallardo‐Godoy, Angélica Fierro, Thomas H. McLean et al. · Journal of Medicinal Chemistry · 2005 · 100 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

Andreas Varkaris, Ermira Pazolli, Hakan Günaydin et al. · Cancer Discovery · 2023 · 90 citations · Full text

Life Sciences, Medicinal Chemistry, Oncology +17

Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2

Heike Schönherr, Pelin Ayaz, Alexander M. Taylor et al. · Proceedings of the National Academy of Sciences · 2024 · 66 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14